Pre-order Enquiry
Request Free Sample
Global Epigenetics Market Research Report 2019-2023
SKU ID : 9DR-14314198 | Publishing Date : 07-Jun-2019 | No. of pages : 142
The prevalence of cancer and other diseases with epigenetic modification will fuel Epigenetics market growth, the global epigenetics market is expected to reach $12.8 Billion by 2020.
By product, Epigenetic reagents was the largest market valued at over USD 1.72 billion in 2016 owing to the increasing amount of R&D investments and high consumption rates. Kits are expected to gain rapid growth in demand due to the increasing need of rapid and accurate detection techniques; additionally, new upgraded kits for easy and efficient detection of biomarkers will foster the growth.
In terms of technology, DNA methylation was the largest technology sect accounting for over 50% revenue in 2016. The introduction of technological advancement such as Methylation Sensitive PCR (MSP) and rapid adoption of these products to improve diagnostics efficiency are some factors attributing for its largest share.
On the basis of application market, oncology was the largest application market, with revenue valued at over USD 3.07 billion. Growing prevalence of cancer with epigenetic modification base and strong product pipeline are some factors attributing to its market position.
Geographically, North America was witnessed to be the largest regional epigenetics market accounting for over 41.0% of the overall revenue, Asia is expected to be fastest growing region with a CAGR of 12.4% over 2016-2020.
World leading players of the epigenetics market include Illumina, Abcam, Diagenode, Thermo Fisher Scientific, Merck, Zymo research, Qiagen, CellCentric Ltd, Chroma Therapeutics Ltd, Eisai Co. Ltd, Novartis International AG, Oncolys Biopharma Inc., Syndax Pharmaceuticals, Inc., Valirx Plc and Sigma-Aldrich Corporation.
Epigenetics Report by Material, and Geography – Global Forecast to 2023 is a professional and comprehensive research report on the world’s major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China).
The report firstly introduced the Epigenetics basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world’s main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.
By product, Epigenetic reagents was the largest market valued at over USD 1.72 billion in 2016 owing to the increasing amount of R&D investments and high consumption rates. Kits are expected to gain rapid growth in demand due to the increasing need of rapid and accurate detection techniques; additionally, new upgraded kits for easy and efficient detection of biomarkers will foster the growth.
In terms of technology, DNA methylation was the largest technology sect accounting for over 50% revenue in 2016. The introduction of technological advancement such as Methylation Sensitive PCR (MSP) and rapid adoption of these products to improve diagnostics efficiency are some factors attributing for its largest share.
On the basis of application market, oncology was the largest application market, with revenue valued at over USD 3.07 billion. Growing prevalence of cancer with epigenetic modification base and strong product pipeline are some factors attributing to its market position.
Geographically, North America was witnessed to be the largest regional epigenetics market accounting for over 41.0% of the overall revenue, Asia is expected to be fastest growing region with a CAGR of 12.4% over 2016-2020.
World leading players of the epigenetics market include Illumina, Abcam, Diagenode, Thermo Fisher Scientific, Merck, Zymo research, Qiagen, CellCentric Ltd, Chroma Therapeutics Ltd, Eisai Co. Ltd, Novartis International AG, Oncolys Biopharma Inc., Syndax Pharmaceuticals, Inc., Valirx Plc and Sigma-Aldrich Corporation.
Epigenetics Report by Material, and Geography – Global Forecast to 2023 is a professional and comprehensive research report on the world’s major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China).
The report firstly introduced the Epigenetics basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world’s main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Request Sample
Request Discount
